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Summary box
 ► Recent studies have shown that mass administration 
of azithromycin in some areas can lead to reduction 
in childhood mortality, which in turn has led to addi-
tional large- scale trials in many parts of the world.
 ► We provide evidence for the emergence of novel 
azithromycin resistance mechanisms in common 
bacterial pathogens like Salmonella, arguing that 
the appealing positive effects of mass drug adminis-
tration might diminish with increasing azithromycin 
resistance.
 ► While a silver bullet against childhood mortality is 
highly desirable, given the alarming rise in antimi-
crobial resistance and the drying pipeline of novel 
drugs, the opportunity costs of mass administration 
should be considered with utmost caution.
 ► Future studies and trials of mass azithromycin 
administration should include methods for early 
detection of azithromycin resistance such that pre-
ventative measures can be implemented, in case 
azithromycin resistance begins to spread.
Azithromycin is an oral macrolide discovered 
in 1980 and approved for medical use in 1988.1 
This relatively inexpensive antibiotic is often 
deemed as a wonder drug due to its safety and 
effectiveness against parasitic and helminth 
infections, in addition to a wide range of bacte-
rial infections. In the early 2000s, biannual 
administration of azithromycin (mass drug 
administration, MDA) for trachoma control 
was found to reduce all- cause mortality by 
almost 49%.2 These encouraging results, 
presumably due to reduction in respiratory 
and diarrhoeal infections3 4 and malaria,5 led 
to the placebo- controlled, double- blinded, 
cluster- randomised MORDOR- I trial (Macro-
lides Oraux pour Réduire les Décès avec un 
Oeil sur la Résistance) in Niger, Malawi and 
Tanzania covering 190 238 children.6 An 
overall 13.5% reduction in child mortality 
was observed in azithromycin versus placebo 
communities; however, the effect was largely 
driven by findings in Niger (18.1%), with 
minimal impact in Malawi (5.7%) and 
Tanzania (3.4%). While the mechanism of 
azithromycin’s effect on childhood mortality 
is not fully understood, the overall success 
of the MORDOR- I trial has led to additional 
trials in various other countries, including 
follow- up trials in Niger and Burkina Faso 
(NCT03676751). Notably, there are ongoing 
clinical trials in Pakistan (NCT03564652 and 
NCT04012177) and a large- scale trial that will 
provide azithromycin to all children at risk of 
diarrhoea in seven countries including Paki-
stan, India and Bangladesh (NCT03130114).
While a silver bullet against childhood 
mortality is highly desirable for vulnerable 
populations, unintended consequences like 
a surge in antimicrobial resistance (AMR) on 
MDA remain a major concern. This is espe-
cially pertinent to the case of azithromycin 
as this antibiotic is becoming the first line of 
treatment of a variety of bacterial infections. 
In 2016, an extensively drug- resistant (XDR) 
strain of Salmonella Typhi caused a large 
outbreak of typhoid fever in Pakistan affecting 
over 10 000 people.7 Resistant to all oral anti-
biotics except azithromycin, this ongoing 
outbreak has become a cause of serious 
concern in the global health community. 
Adding to this concern are recent reports 
of azithromycin- resistant Salmonella Typhi 
strains from Pakistan’s neighbouring coun-
tries, India and Bangladesh.8 Emergence 
of pan- oral drug- resistant (PoDR) Typhi in 
Pakistan or in any typhoid endemic country 
will severely impair our ability to contain this 
disease. At present, majority of patients with 
typhoid are treated with oral antibiotics in 
the community or in the outpatient depart-
ment. Emergence of PoDR Typhi would shift 
the treatment from the outpatient to inpa-
tient departments. Considering the high 
burden of typhoid infections every year and 
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the limited number of hospital beds, PoDR Typhi may 
increase the current mortality rate of <1% to closer to 
that seen in the preantibiotic era (~30%). In addition to 
preventative measures like vaccine, and water, sanitation 
and hygiene (WASH) interventions, the crusade against 
the emergence of PoDR Typhi calls for judicious use of 
azithromycin. Hence in this essay, we advocate for utmost 
discretion moving forward and list key considerations 
that should be taken into account while designing and 
implementing azithromycin MDA studies.
Like other macrolides, azithromycin targets the P- site 
of the 50S subunit of bacterial ribosome, one of the 
most conserved biomolecules in bacteria. Various molec-
ular mechanisms of azithromycin resistance have been 
identified in different bacterial species.1 These include 
acquisition of target modifying enzymes (such as meth-
yltransferases) or macrolide detoxifying enzymes (such 
as esterases, glycosyltransferases and phosphotransfer-
ases) that can be transferred through horizontal gene 
transfer to other bacterial species. Additionally, increased 
expression of efflux pumps has also been found to 
contribute to azithromycin resistance.1 8 A follow- up 
study to MORDOR- I found an increase in isolation of 
macrolide- resistant pneumococcus (12.3% vs 2.9%) 
from the nasopharyngeal cavity, and a higher presence 
of known macrolide resistance markers at both DNA 
(68% vs 46.7%) and RNA (16.7% vs 2.7%) levels in the 
intestinal flora of children treated with azithromycin at 
the Nigerien site.9 The gut microbiome is a reservoir of 
resistance, and instances of transfer of resistance markers 
between resident gut bacteria and pathogenic bacterial 
species are common. Bacterial AMR can very quickly 
spread globally through dissemination and horizontal 
gene transfer between different bacterial species.10 The 
spread of azithromycin resistance would not only lead 
to reduction in the efficacy of MDA over time, but also 
steal one of the few remaining options of cost- effective 
antibiotic to treat specific, life- threatening bacterial 
infections. While two ongoing MDA trials will monitor 
azithromycin resistance mechanisms (NCT03676751 and 
NCT03130114), we recommend that all future studies 
should include methods for early AMR detection such 
that preventative measures can be implemented, in case 
azithromycin resistance begins to spread.
Another key concern is that current molecular tech-
niques may grossly underestimate azithromycin resistance 
as the known resistance mechanisms most likely repre-
sent a proportion of all the potential modes of azithro-
mycin resistance. Recently, our group demonstrated that 
a point mutation at position 717 (R717Q/L) in the efflux 
pump AcrB can lead to azithromycin resistance in Salmo-
nella Typhi and Paratyphi A (causative agent of paraty-
phoid fever).8 The MORDOR studies did not look at the 
abundance of AcrB variants in the studied population.9 
To determine the global distribution of this particular 
mutation, we searched for the AcrB R717Q/L variants 
in sequenced strains of typhoidal (Typhi and Paratyphi 
A) and major non- typhoidal serovars (Typhimurium 
and Enteritidis) of Salmonella. The latter two serovars 
are the most common causes of non- typhoidal salmo-
nellosis that can lead to case fatality rates of 20%–25% 
in sub- Saharan Africa and azithromycin is often used as 
the drug of choice.11 Given their genomic similarity to 
typhoidal Salmonella, AcrB R717Q/L mutations are likely 
to cause azithromycin resistance in these serovars. In 
total, we searched 49 115 Salmonella genomes (Enteritidis 
(n=23 661), Typhimurium (n=17 076), Typhi (n=7136) 
and Paratyphi A (n=1242)) available in EnteroBase, a 
genome database of enteric bacteria.12 The R717Q/L 
mutation was found in 86 strains (Enteritidis (n=61), 
Typhimurium (n=8), Typhi (n=16), Paratyphi A (n=1)). 
This mutation was most commonly found in the strains 
from the UK (figure 1), which is not surprising as the 
UK also had the highest number of sequenced strains 
(n=22 161). As more strains of Salmonella are sequenced 
from developing countries, especially from sub- Saharan 
Africa and South Asia, where most MDA trials are under 
way, we predict that more AcrB R717Q/L mutations will 
be identified. In addition, as azithromycin usage increases 
in populations, the acquisition of such novel mechanisms 
(eg, mutations) may accelerate. These novel mutations 
will be harder to predict compared with known resistance 
markers, yet could spread fast globally and to other bacte-
rial species. To overcome these limitations, we need to 
continuously update the list of potential modes of azith-
romycin resistance and also help fund basic laboratory 
and computational/machine- learning studies to estimate 
the potential routes through which azithromycin resis-
tance may emerge.
Furthermore, when designing studies or interpreting 
results for MDA trials, it is important to note that antibi-
otic consumption rates differ between and within coun-
tries. The increase in resistance seen in the 2 years of 
MORDOR- I did not contribute to a decrease in efficacy 
over the following year during the longer term follow- up 
in MORDOR- II.13 Furthermore, studies conducted after 
azithromycin MDA for trachoma control showed that 
when administration was stopped, resistance returned 
to near- baseline levels.13 However, it is important to note 
that the trachoma control and MORDOR- II studies were 
primarily conducted in very poor regions of sub- Saharan 
African countries, where the rates of antibiotic exposure 
are low. As countries develop, antibiotic consumption, 
especially over- the- counter antibiotic usage, increases and 
this can lead to unexpected increase in the rate of acqui-
sition of azithromycin resistance.14 Of special concern are 
places like Pakistan, where due to the outbreak of XDR 
Typhi azithromycin usage has already shot up.7 Large- 
scale azithromycin administration in Pakistan would 
increase the chance of emergence of PoDR Typhi strains. 
Hence, in the MDA studies, special attention should be 
given to pathogens relevant to the local populations. The 
incidence of typhoid and paratyphoid fever is 549.2 and 
219.2 per 100 000 in South and South- East Asia, respec-
tively.15 The incidence of non- typhoidal Salmonella is 34.3 
per 100 000, with mortality rates greater than 100 per 
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Figure 1 Global distribution of pathogenic Salmonella isolates with AcrB mutations associated with macrolide resistance. 
Genomes of four pathogenic Salmonella serovars—Enteritidis, Typhimurium, Typhi and Paratyphi A—present in the online 
database EnteroBase (downloaded May 2019) were screened for the presence of AcrB R717Q/L mutations. The countries are 
shaded based on the number of strains sequenced, and countries in white had no sequenced Salmonella strains. Countries 
from which AcrB R717Q/L- containing strains could be identified are highlighted, and the number of strains found in each 
country is shown as a pie chart, where the size of the pie represents the number of strains identified with mutation and colours 
represent the different serovars.
million in sub- Saharan countries such as Burkina Faso, 
Niger and Mali.11 Hence, rising azithromycin resistance 
in Salmonella species is of serious concern and should be 
monitored in future azithromycin MDA studies.
Lastly, there are many intervention strategies by which 
childhood mortality can be improved that do not require 
antibiotic usage. In areas with limited resources the costs 
of MDA studies may divert resources and attention away 
from other intervention strategies such as improvements 
in antenatal and neonatal nutritional supplements, 
developments in WASH and so on. Future azithromycin 
MDA studies must be integrated into health systems such 
that they can strengthen existing or new child survival 
interventions.
Given the alarming rise in AMR and the drying pipe-
line of novel drugs, the opportunity costs of MDA should 
be considered with utmost caution. The appealing posi-
tive effects of azithromycin MDA are likely to diminish 
with the inevitable rise of azithromycin resistance, leaving 
a narrow window where such strategies can have maximal 
impact. Indiscriminate use of antibiotics may lead to 
unrecoverable loss of an extremely precious commodity.
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